New Frontiers: Research Advances for High-Risk and Advanced Prostate Cancer

Beyond imaging and genetic testing, several distinct lines of research reported in 2026 are reshaping how doctors think about high-risk […]

The Genetic Turn: PARP Inhibitors Move Earlier in Prostate Cancer Treatment

One of the most consequential developments in prostate cancer research this year has nothing to do with a new drug […]

Seeing and Striking the Target: How PSMA Is Transforming Prostate Cancer Care

Prostate cancer research in 2026 has been defined by a single molecule: PSMA, or prostate-specific membrane antigen. This protein sits […]

PARP Inhibitors: Recent Research Advancements in Prostate Cancer (2025–2026)

PARP inhibitors are among the most significant advances in precision medicine for prostate cancer. These drugs work by blocking DNA […]

Two New Approvals, One Clear Direction — Targeted Drug Therapies Come of Age in 2025

The past year brought two significant FDA approvals that signal where prostate cancer treatment is heading: toward more precise, earlier-acting […]

“Smart” Radiation Gets Smarter — Lutetium-177 Therapy Expands Its Reach

A treatment once reserved for men who had exhausted nearly every other option is now available earlier in the course […]

A New Standard in Detection — PSMA PET Imaging Is Changing How We Find Prostate Cancer

For decades, diagnosing and staging prostate cancer relied on a combination of CT scans, bone scans, and MRI. That picture […]